Gastrointestinal adverse events occurred in 79.6% of CagriSema participants versus 39.9% with placebo, were mostly transient, and led to discontinuation in 6-8.4% of participants
The compound did not advance to Phase 3 because the efficacy was insufficient for drug approval
Adding Exercise to GLP1 Therapy Improves Long-Term Benefits, Multinational Study Finds The combination could save billions in healthcare costs, leading fitness organizations to call for deeper integration of structured exercise in GLP-1 treatment
The best approach is layered and nuanced, designed to tackle the problem from multiple angles
John Batsis, a geriatrician and obesity specialist at the University of North Carolina School of Medicine, told The New York Times in a recent report that people over 65 years old are "prime targets" for this medication, as obesity prevalence is about 40% in older adults
GLP-1 Medication + Medical Care With this package, you get oral tirzepatide medication + medical care as part of your $249 first month membership